Reassortant Or Deletion Mutant Virus Patents (Class 424/205.1)
  • Patent number: 10240131
    Abstract: The present invention discloses a type II Pseudorabies virus attenuated strain and its preparation method and application. The attenuated strain of pseudorabies virus is gE/TK-double-deficient strain, which is named as PRV-HD/c strain of PRV dual-deletion strain, and the accession number is CGMCC No. 14325. The attenuated strain of the pseudorabies virus of the present invention is obtained from the newly isolated strain of pseudorabies virus type II after deletion of the gE and TK double genes and has reduced pathogenicity and strong immunogenicity and is inactivated by the attenuated strain of pseudorabies virus vaccines or live attenuated vaccines, which can provide effective immunity to PRV susceptible animals such as pigs and mice.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 26, 2019
    Assignee: ZHEJIANG UNIVERSITY
    Inventors: Jiyong Zhou, Gang Xing, Yulan Jin, Jinyan Gu, Yan Yan, Min Liao, Xiaojuan Zheng, Weiren Dong
  • Patent number: 10166285
    Abstract: The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: January 1, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Jeffrey I. Cohen, Lesley Pesnicak
  • Patent number: 10131696
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Patent number: 9999665
    Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: June 19, 2018
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: William Jacobs, Jr., Pablo A. Gonzalez Munoz, Betsy Herold, Christopher Petro
  • Patent number: 9956280
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: May 1, 2018
    Assignee: Novavax, Inc.
    Inventors: Robin A. Robinson, Peter M. Pushko
  • Patent number: 9937253
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: April 10, 2018
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 9855327
    Abstract: The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD).
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: January 2, 2018
    Assignee: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
    Inventors: Xiang-Jin Meng, Nathan M. Beach, Sheela Ramamoorthy
  • Patent number: 9795665
    Abstract: The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 24, 2017
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
  • Patent number: 9650424
    Abstract: Provided in the embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 16, 2017
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Xuke Zhang, Jinzhong Sun, Rui Wu, Feifei Tan, Chaoyong Bai, Kegong Tian
  • Patent number: 9623099
    Abstract: The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is F. psychrophilum and/or infectious pancreatic necrosis virus (IPNV).
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: April 18, 2017
    Assignee: FVG Limited
    Inventors: Elizabeth Mary Crump, Jan Burian, Joseph Michale Bricker, William Wayne Kay, Norman William Johnson
  • Patent number: 9610344
    Abstract: The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD).
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: April 4, 2017
    Assignee: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
    Inventors: Xiang-Jin Meng, Nathan M. Beach, Sheela Ramamoorthy
  • Patent number: 9585951
    Abstract: The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD).
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: March 7, 2017
    Assignee: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
    Inventors: Xiang-Jin Meng, Nathan M. Beach, Sheela Ramamoorthy
  • Patent number: 9541553
    Abstract: This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: January 10, 2017
    Assignee: Oregon Health & Science University
    Inventors: Louis Picker, Klaus Frueh, Scott G. Hansen, Collin Powers
  • Patent number: 9474799
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: October 25, 2016
    Assignee: Novavax, Inc.
    Inventors: Robin A. Robinson, Peter M. Pushko
  • Patent number: 9457075
    Abstract: The present invention provides a foot-and-mouth diseases virus (FMDV) VP1 capsid protein which comprises an entity of interest (EOI). The EOI sequence may, for example, be an epitope tag, an immunomodulatory molecule or a target molecule. The present invention also provides an FMDV vaccine which comprises such a VP1 capsid protein and its use to prevent FMD.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: October 4, 2016
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Julian Seago, Nicholas Juleff
  • Patent number: 9169297
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: October 27, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • Publication number: 20150140035
    Abstract: The present disclosure relates to an autologous biological cancer vaccine and to a method for preparing the same. The vaccine of the present application is a biological vaccine obtained from overexpressed proteins in the serum of cancer patients, proteins to which have been added immunological adjuvants such as an attenuated virus DNA and amino acids in order to cause an immune response, blocking tumor cells. The preparation method includes obtaining the antigen associated with the tumor as well as the vaccine preparation with attenuated virus DNA, combining the components under conditions that have been determined by experimentation, filtration and refrigeration.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventor: Hugo Ramiro Segura Puello
  • Patent number: 9028838
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: May 12, 2015
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble
  • Patent number: 9028837
    Abstract: The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: May 12, 2015
    Assignee: East Carolina University
    Inventor: Rachel Roper
  • Patent number: 8986705
    Abstract: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: March 24, 2015
    Assignee: MedImmune, LLC
    Inventors: George Robert Trager, Vu Truong-Le, Luisa Yee
  • Patent number: 8932607
    Abstract: Described is a composition comprising a plurality of recombinant adenovirus particles, being a recombinant human adenovirus of serotype 5, 26, 34, 35, 48, 49 or 50, or a recombinant simian adenovirus, characterized in that the genomes of essentially all adenovirus particles in the composition comprise as the 5? terminal nucleotides the nucleotide sequence: CTATCTAT (nucleotides 1-8 of SEQ ID NO:7). Also described are methods to produce such compositions.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 13, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Jerome H. H. V. Custers, Jort Vellinga
  • Patent number: 8932604
    Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: January 13, 2015
    Assignee: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Gary Petersen, Paulus Jacobus Antonius Sondermeijer
  • Patent number: 8916371
    Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 23, 2014
    Assignee: Merial Limited
    Inventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
  • Patent number: 8895025
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: November 25, 2014
    Assignee: Zoetis LLC
    Inventors: Jay Gregory Calvert, Michael G. Sheppard, Siao-Kun W. Welch, Raymond R. R. Rowland, Dal-Young Kim
  • Patent number: 8895026
    Abstract: The present invention relates to recombinant attenuated pestiviruses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric Erns glycoprotein. The present invention also relates to immunogenic compositions comprising such a pestivirus as well to a method of attenuating a pestivirus comprising the step of modifying the Erns glycoprotein by a deletion, insertion or substitution wherein such modification results in a non dimeric Erns glycoprotein.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: November 25, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Gregor Meyers, Birke Andrea Tews, Eva-Maria Schuermann
  • Patent number: 8883168
    Abstract: The present invention relates to compositions, methods, and uses involving the modulation of K4 protein activity, especially in the treatment of various diseases and in the enhancement of vaccination regimens. The invention relates to poxviruses having reduced or increased K4 protein activity, as well as methods of making and using these poxviruses. The invention further relates to K4 proteins and inhibitors of K4 protein activity, as well as methods for making and using them.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 11, 2014
    Assignee: Bavarian Nordic A/S
    Inventors: Jürgen Hausmann, Hubertus Hochrein, Christine Meisinger-Henschel
  • Patent number: 8877209
    Abstract: The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: November 4, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann
  • Patent number: 8877211
    Abstract: A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 UL49.5?30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g., the glycoprotein E cytoplasmic-tail deletion, the Us9 deletion, or both. This triple mutant BHV-1 UL49.5?30-32 CT-null/gE CT?/Us9? virus will be superior to the current BHV-1 mutants because the mutant virus will not be shed following reactivation, will be a DIVA based on gE CT-specific serum antibodies, and will induce better protective response by inducing higher SN titers and better cellular immune response. This new virus will have sufficient viral replication in the nasal epithelium and will be a good vaccine for protection of cattle from BHV-1. The new mutant viruses can also be used as vectors for exogenous genes.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 4, 2014
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Shafiqul I. Chowdhury, Hui Yong Wei
  • Patent number: 8858948
    Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: October 14, 2014
    Assignee: Theraclone Sciences, Inc.
    Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
  • Publication number: 20140302088
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 9, 2014
    Applicants: The Government of the United States of America as Represented by the Secretar, INVIRAGEN, INC.
    Inventors: Daniel T. Stinchcomb, Claire Y Huang, Richard M Kinney, Jill A Livengood
  • Patent number: 8846055
    Abstract: Classical Swine Fever Virus (CSFV) E2 glycoprotein is a major inducer of neutralizing antibodies and protective immunity in swine. E2 mediates virus adsorption to the target cell, and harbors genetic determinants associated with virus virulence. CSFV E2 also contains between residues 829 and 837 a discrete epitope (TAVSPTTLR) recognized by monoclonal antibody (mAb) WH303, used to differentiate CSFV from related Pestiviruses Bovine Viral Diarrhea Virus (BVDV) and Border Disease Virus (BDV). In this report, a CSFV infectious clone of the virulent Brescia isolate (BICv) was used to progressively mutate the mAb WH303 epitope of CSFV E2 to the homologous amino acid sequence of BVDV strain NADL E2 (TSFNMDTLA).
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 30, 2014
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Manuel V. Borca, Guillermo R. Risatti
  • Publication number: 20140271709
    Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Inventors: Brad Eddy, Zhisong QIAO, Kevin O'Connell
  • Patent number: 8834893
    Abstract: The present invention provides a nucleic acid comprises a 5? untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3? untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: September 16, 2014
    Assignees: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Institute of Medical Science
    Inventors: Takaji Wakita, Tomoko Date, Hitoshi Takahashi
  • Patent number: 8821897
    Abstract: The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: September 2, 2014
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Robert E. Johnston, Joseph M. Thompson
  • Patent number: 8815252
    Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: August 26, 2014
    Assignee: Baxter Healthcare SA
    Inventors: Julia Romanova, Andrej Egorov, Brigitte Krenn, Markus Wolschek, Sabine Nakowitsch
  • Patent number: 8802109
    Abstract: A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: August 12, 2014
    Assignees: University of Kansas, Southern Illinois University
    Inventors: David Davido, William Halford
  • Publication number: 20140205620
    Abstract: Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins and for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.
    Type: Application
    Filed: June 1, 2012
    Publication date: July 24, 2014
    Applicant: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY
    Inventor: Antonius G.P. Oomens
  • Patent number: 8784836
    Abstract: Therapeutic methods and vaccinia virus therefor are provided. The viruses are designed so that they accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. Combinations of the viruses and anti-cancer agents and uses thereof for treating cancer also are provided.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: July 22, 2014
    Assignee: Genelux Corporation
    Inventors: Aladar A. Szalay, Tatyana Timiryasova, Yong A. Yu, Qian Zhang
  • Patent number: 8778354
    Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ralph A. Tripp, Les Jones, Larry J. Anderson
  • Patent number: 8778355
    Abstract: The invention belongs to the field of animal health and in particular Bovine Viral Diarrhea Virus (BVDV). The invention provides infectious BVDV clones and methods to produce said BVDV clones. The invention further relates to methods of attenuating said clones, attenuated BVDV clones and vaccines comprising said attenuated clones.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: July 15, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Knut Elbers, Christiane Fetzer, Martina von Freyburg, Gregor Meyers
  • Patent number: 8765141
    Abstract: We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: July 1, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Aida E. Rieder, Luis L. Rodriguez, Jason R. Hollister, Sabena Uddowla
  • Publication number: 20140127261
    Abstract: Mutations in the central monomer contact interface of the flavivirus envelope protein which modulate the infectivity of the flavivirus are made. The mutations decrease the ability of the envelope dimer protein to dissociate.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 8, 2014
    Applicant: Southern Research Institute
    Inventor: Vladimir Yamshchikov
  • Patent number: 8691238
    Abstract: The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 8, 2014
    Assignee: Baxter Healthcare SA
    Inventors: Thomas Muster, Markus Wolschek, Andrej Egorov, Elisabeth Roethl, Julia Romanova, Michael Bergmann
  • Patent number: 8691239
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: April 8, 2014
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
  • Patent number: 8679509
    Abstract: The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: March 25, 2014
    Assignee: The Governors of the University of Alberta
    Inventors: David H. Evans, Don B. Gammon
  • Patent number: 8673315
    Abstract: The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: March 18, 2014
    Assignee: London School of Hygiene & Tropical Medicine
    Inventors: Polly Roy, Mark Boyce
  • Patent number: 8663653
    Abstract: The present inventors developed hepatitis C virus 2b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 2b reference strain J8. Sequence analysis of recovered 2b/2a recombinants from 2 transfection experiments revealed that 2b/2a was genetically stable. Conclusion: The developed 2b/2a viruses provide a robust in vitro tool for research in HCV genotype 2b, including vaccine studies and functional analysis.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: March 4, 2014
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Maria Lisa Knudsen, Troels Kasper Høyer Scheel, Jens Bukh
  • Patent number: 8658610
    Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: February 25, 2014
    Assignee: Saint Louis University
    Inventors: William S. M. Wold, Karoly Toth, Konstantin Doronin, Ann E. Tollefson
  • Publication number: 20140050761
    Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 20, 2014
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
  • Publication number: 20140030290
    Abstract: An infectious clone based on the genome of a wild-type RNA virus is produced by the process of providing a host cell not susceptible to infection by the wild-type RNA virus, providing a recombinant nucleic acid based on the genome of the wild-type RNA virus, transfecting the host cell with the recombinant nucleic acid and selecting for infectious clones. The recombinant nucleic acid comprises at least one full-length DNA copy or in vitro-transcribed RNA copy or a derivative of either. The infectious clones can be used in single or dual purpose vaccines and in viral vector vaccines.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Johanna Jacoba Maria Meulenberg, Johannes Maria Antonius Pol, Judy Norma Aletta Bos-de Ruijter